Quantcast
Channel: Europe Headlines on One News Page [United Kingdom]
Viewing all 65275 articles
Browse latest View live

Wildix to Showcase Expansive WebRTC-powered Unified Communications & Collaboration Portfolio at Enterprise Connect 2018

March 12, 2018, 6:21 am
$
0
0
Multi-national provider of telecom solutions is first to fully integrate WebRTC for direct audio and video communication support in the web browser, without any software installation or VPN configuration

ORLANDO, Fla., March 12, 2018 (GLOBE NEWSWIRE) -- Wildix, a multinational telecommunications provider specializing in WebRTC Browser-Based Unified Communications and Collaboration (UC&C) solutions, today announced that it will showcase its expansive portfolio from BOOTH 2315 at Enterprise Connect, March 12 – 15^, 2018, in Orlando, Florida.

Founded in 2005, Wildix, with offices across the EMEA and now the US, is the first vendor to fully integrate WebRTC for direct audio and video communication support in the web browser without the need for software installation or VPN configuration. Wildix also offers the only browser-based WebRTC phone for audio and video calls.

The company, which utilizes a channel-only sales model, achieved significant growth in its partner ecosystem in 2017. Since arriving in the US, Wildix has booked more than 50 partners across North America.

Wildix Collaboration is a WebRTC browser-based offering that enables simple, instant and secure communications. Users can access Wildix Collaboration tools from any location, using any device, regardless of the OS, and without having to install any components.

The innovative UCaaS suite boasts features and functionality including presence, remote desktop control, attendant console, file sharing, video conferencing, live streaming to Facebook and YouTube, and more. ubiconf, the company’s flexible videoconferencing solution, is based entirely on WebRTC and is accessible to corporate and public users with one click. Communicating presence information and geolocation, users can monitor in real time who is online, absent, busy in another conversation, or does not want to be disturbed.

Fully integrated into the collaboration platform, Wildix Kite is a value-added service that leverages WebRTC to extend UC to an organization’s public website. Not only does it show employees’ presence in their personal contact information, Kite also allows visitors to engage representatives via chat, voice, audio and video calling, desktop sharing and file transfer, all with just one click.

“Wildix was founded with a singular mission to seamlessly unify internal and external communications across all platforms, while continuing to embrace new technology,” said Robert Cooper, GM, Wildix US. “We are excited to show Enterprise Connect attendees how for more than 13 years, Wildix has empowered businesses worldwide with tools that are as functional as they are easy to use, and that increase employee efficiency and productivity while helping them achieve new heights of agility.”

In addition to its UC&C software and software and services, Wildix also offers a wide range of hardware. Wildix-Huddle, an uncompromising Huddle Room gathering device, comes equipped with a 120° angle webcam, frames all meeting participants, is plug and play, and needs only one cable. The company’s new Vision phone brings a 7"screen, as well as a 2-megapixel camera that integrates WebRTC technology on Android OS.

For more than 27 years, Enterprise Connect has been the leading conference and exhibition for enterprise communications and collaboration in North America. Enterprise Connect brings corporate IT decision makers together with the industry's vendors, analysts and consultants to focus on the issues central to enterprise communications and collaboration.

To learn more about Wildix, please visit www.wildix.com.

*ABOUT ENTERPRISE CONNECT*
For more than 27 years, Enterprise Connect has been the leading conference and exhibition for enterprise Unified Communications and Collaboration in North America. Enterprise Connect brings corporate IT decision makers together with the industry's vendors, analysts, and consultants to focus on the issues central to enterprise networks and communications. Enterprise Connect owns and produces No Jitter, (nojitter.com), providing daily blogging and analysis of enterprise communications, and it also serves the community with a weekly email newsletter, research surveys, and a Webinar Series. For more information, visit enterpriseconnect.com.

Enterprise Connect is organized by UBM plc. UBM is the largest pure-play B2B Events organizer in the world. Our 3,750+ people, based in more than 20 countries, serve more than 50 different sectors. Our deep knowledge and passion for these sectors allow us to create valuable experiences which enable our customers to succeed. Please visit www.ubm.com for the latest news and information about UBM.

*ABOUT WILDIX*
Wildix is a multinational company that develops browser-based Unified Communications solutions and VoIP products. The company relies on a network of Certified Business Partners that install Wildix systems in Europe and in the United States. In 2005, Wildix founded its Research and Development center in Ukraine. Headquartered in Italy, Wildix operates sales offices in France, Germany, the Netherlands and the USA.

*CONTACT*
Mostafa Razzak
JMRConnect
202.904.2048
m.razzak@jmrconnect.net Reported by GlobeNewswire 30 minutes ago.
↧
Search
↧

Win EIGHT days of unlimited rides as one of Europe’s biggest street fairs comes to Boston

March 12, 2018, 6:32 am
$
0
0
Win EIGHT days of unlimited rides as one of Europe’s biggest street fairs comes to Boston The fair opens on May 5 Reported by Boston Target 19 minutes ago.
↧

2 surprising charts show traders aren't losing sleep over a trade war

March 12, 2018, 6:43 am
$
0
0
2 surprising charts show traders aren't losing sleep over a trade war· *A widespread narrative around a possible global trade war is that it would hurt the most internationally exposed companies.*
· *Goldman Sachs says this isn't true, and has two charts to prove it.*

--------------------

One of the most widespread narratives in the market right now is that President Donald Trump's newly announced tariffs on steel and aluminum will result in a global trade war as other countries retaliate.

And since the largest companies in major indexes tend to be the ones who conduct the most business overseas, there's been some apprehension around the overall health of the stock market.

Goldman Sachs says not so fast. The firm argues the market has held up just fine in the face of trade wind fears, and it has two charts to prove it.

The first one shows stock prices for companies that have high imported costs of good sold — such as agriculture firms, luxury consumer companies, and media and telecom corporations — have "generally demonstrated no signs of concern." This can be seen by their relatively flat indexed performance.

The second chart provided by Goldman highlights the surprising outperformance of US stocks that have both high international sales and specific exposure to Europe and China. The strength shown by both groups is perhaps the most direct refutation of the "trade war is bad for mega-cap US stocks" narrative.

Goldman does note, however, that small-cap stocks — or those with presumably the least exposure to a trade war — have outperformed the broader market in recent weeks. And while there's no denying small-caps have been a good place to be during that period, Goldman argues the group's outsized returns are more a reflection of it playing catch-up after lagging for months.

"Although equity prices have moved in reaction to the proposed metals tariffs, investors do not appear concerned about escalating trade conflict," David Kostin, Goldman's head of US equity strategy, wrote in a client note.

*SEE ALSO: An inside look at CVS' $40 billion bond deal, one of the biggest of all time, from the lead bankers' perspective*

Join the conversation about this story »

NOW WATCH: The science of why human breasts are so big Reported by Business Insider 7 minutes ago.
↧

Hi Technological Plastic Industries PLC: has entered agreement with Luxembourg Law Firm to become listed on the Luxembourg Stock Exchange

March 12, 2018, 6:44 am
$
0
0
DGAP-News: Hi Technological Plastic Industries PLC / Key word(s): Letter of Intent/Miscellaneous

12.03.2018 / 14:22
The issuer is solely responsible for the content of this announcement.
--------------------

Hi Technological Plastic Industries PLC is pleased to announce, that the Company is now officially in the process of getting listed at the prestigious Bourse De Luxembourg (Luxembourg Stock Exchange). The Company will keep all its investors informed regards the progress of the listing on the Regulated Market, which entails an European Prospectus with the ability for admission to trading of the equities in other EU member states. It is estimated by the Law Firm, that the listing may be completed in the third quarter of 2018.

"This is a great opportunity for Hi Technological Plastic Industries PLC to be recognized in Europe, create interest among investors and raise capital for our continues growth", said Shahid Akram, Director of Operations.

"Company is poised to triple its revenues and profits provided it can raise Euro 8,000,000 in 2018", said Rana Kashaf Shahzad, Chairman of Hi Technological Plastic Industries LLC.

*About*
Hi Technological Plastic Industries PLC is the holding company of the operational Hi Technological Plastic Industries LLC based in UAE since 2013 and is in the business of manufacturing LDPE recycling Granule, HDPE/LDPE & PVC Pipe with a capacity of 300 metric tons. UAE is the main market for the products, but the products are also exported worldwide, where the main export markets are Pakistan, India, China, Hong Kong and East African countries. In 2017 the company had a revenue of Euro 14.324.556 and a gross profit of Euro 2.277.813
--------------------

12.03.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de -------------------- Reported by EQS Group 7 minutes ago.
↧

Cast Iron Cookware Market to be worth US$3,303.0 mn by 2025 - TMR

March 12, 2018, 6:36 am
$
0
0
ALBANY, New York, March 12, 2018 (GLOBE NEWSWIRE) -- The vendor landscape of the *global cast iron cookware market* is primarily characterized by a high level of fragmentation owing to the presence of several multinationals as well as a large number of unorganized domestic players in key regional markets. Increasing competition among key players is the main challenge for cast iron cookware manufacturers, which is likely to lead to a decrease in profit margins. As competition intensifies in this sector, with price wars raging among leading players, industry players are expected to put increased focus on improving the efficiency of their value chain, from inbound logistics to distribution, and to a large extent, the marketing and export of products.

Additionally, companies are also trying to introduce a range of differentiated products and packaging for a high margin business segment, in order to cater to the evolving needs of customers, along with enhancing their customer base. Some of the leading companies in the market are Tramontina USA, Inc., The Coleman Company, Inc., Lodge Manufacturing Company, FINEX Cast Iron Cookware Co., Staub USA, Inc., and Le Creuset of America.

*Get Sample Brochure at* https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=40196

According to the report, the global cast iron cookware market is likely to expand at a CAGR of 3.4% from 2017 to 2025, rising from a valuation of nearly US$2,537.0 mn in 2017 to nearly US$3,303.0 mn by 2025. Of the key end-use consumer segments of cast iron cookware, the segment of food services accounted for the dominant 67.6% share of the overall market. Geographically, the market in Asia Pacific is likely to dominate the overall market in terms of demand through 2025, followed by the markets in Europe and North America.

*Rising Consumer Awareness about Health Issues Associated with Non-stick and Aluminum Cookware to Work Well for Cast Iron Cookware Industry*

The increasing one-person households across the globe is a substantial global demographic change having extensive consequences, and is having deep implications on a number of businesses ranging from housing to healthcare. This trend is also expected to lead to a surge in the global demand for cast iron cookware in the near future. Over the last few years, consumer behavior has drastically changed and consumers are more inclined towards researching about products online and purchasing various types of cookware such as such as electric, non-stick, and cast iron cookware through e-Commerce websites. As such, the increased awareness regarding the health issues associated with coatings on non-stick cookware and aluminum products and the flourishing market for online retailing are boosting the cast iron cookware market.

*Request a Sample of Cast Iron Cookware Market at *https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=40196

Moreover, unique properties of cast iron cookware such as high durability, effective heat distribution, and the fact that cast iron cookware leach iron into the food during the cooking process, which may be helpful for iron deficiency problems, are also working in favor of the market.

*Easy Availability of Lighter and Cheaper Alternatives to Negatively Affect Cast Iron Cookware Consumption Globally*

One of the key challenge that is restricting the adoption of cast iron cookware is the fact that cast iron cookware is much heavier than cookware made from other materials such as aluminum and stainless steel. Furthermore, cast iron cookware is not recommended for use on glass cooktops. Glass stove tops require more careful use than coil tops and dragging the heavy cast iron cookware over glass cooktops can scratch the glass surface. Moreover, cast iron cookware is slow to absorb heat, and may damage the heating elements or break the glass stove top. Cast iron cookware with enameling at the bottom is equally unsafe on a glass cooktop.

*Get Discount on this Report at *https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=40196

Furthermore, the global cookware market offers several alternatives such as aluminum, stainless steel, copper, and non-stick cookware. Stainless steel cookware are non-reactive, durable, and resistant to rust, dishwasher safe, corrosion, scratching, and denting. They last well and can be cleaned with heavy brushes or dishwashers without damage. Moreover, low cost of these alternatives could also challenge the overall cast iron market.

This analysis of the global cast iron cookware market is based on a recent market research report by Transparency Market Research, titled “*Cast Iron Cookware Market (Product Type- Unseasoned, Seasoned, and Enamel Coated; End-use- Household and Food Services; Style- Dutch Ovens, Camp Pots, Skillets/ Fryers, Woks, Griddles, and Bake Ware; Sales Channel- Direct, Indirect (Modern Grocery Retailers and Traditional Grocery Retailers), and Online Retail) - Global Industry Analysis and Opportunity Assessment, 2017-2025*.”

*Browse Press Release at *https://www.transparencymarketresearch.com/pressrelease/cast-iron-cookware-market.htm

*About Us*

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

*Contact Us*

Mr. Atil Chaudhari
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com
Research Blog: http://www.techyounme.com/ Reported by GlobeNewswire 15 minutes ago.
↧
↧

PCI Biotech to present at Bio-Europe Spring 2018

March 12, 2018, 6:43 am
$
0
0
Oslo, Norway, March 12, 2018 PCI Biotech (OSE:PCIB), a clinical-stage company developing innovative therapeutics that address significant unmet medical needs, today announced that it will present at Bio-Europe Spring 2018 being held March 12-14, 2018 at the Amsterdam RAI Convention Center, Amsterdam, The Netherlands.

On Wednesday, March 14, 2018 at 10:15am (CET), Mr. Gaël L'Hévéder, CBDO, will present an overview of PCI Biotech's technology and the multiple business development and commercial opportunities available based on this proprietary platform. The presentation will be made available on PCI Biotech's website (www.pcibiotech.com ) under "Other presentations".

*About PCI Biotech          *
PCI Biotech is a biopharmaceutical company focusing on development and commercialisation of novel therapies for the treatment of cancer through its innovative photochemical internalisation (PCI) technology platform.  PCI is applied to three distinct anticancer paradigms: *fimaChem* (enhancement of chemotherapeutics for localised treatment of cancer), *fimaVacc* (T-cell induction technology for therapeutic vaccination), and *fimaNAc *(nucleic acid therapeutics delivery).

Photochemical internalisation induces triggered endosomal release that is used to unlock the true potential of a wide array of therapeutic modalities. The company's lead *fimaChem* programme consists of a clinical Phase I/II clinical study in bile duct cancer, an orphan indication with a high unmet need and without approved products. *fimaVacc* applies a unique mode of action to enhance the essential cytotoxic effect of therapeutic cancer vaccines, which works in synergy with several other state-of-the-art vaccination technologies. *fimaNAc* utilises the endosomal release to provide intracellular delivery of nucleic acids, such as mRNA and siRNA therapeutics, thereby addressing one of the major bottlenecks facing this emerging and promising field.
*
Contact information:   
*PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo, Norway. www.pcibiotech.com      
Ronny Skuggedal, CFO, rs@pcibiotech.no, Mobile: +47 9400 5757.

Forward-looking statements  
This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements. PCI Biotech disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act. Reported by GlobeNewswire 7 minutes ago.
↧

Mono Bluetooth Headsets Market to be worth US$ 6 Bn by 2026 - TMR

March 12, 2018, 6:44 am
$
0
0
ALBANY, New York, March 12, 2018 (GLOBE NEWSWIRE) -- The *global mono Bluetooth headsets market* has been thoroughly analyzed by Transparency Market Research (TMR). The research report covers market intelligence on mono Bluetooth headsets that includes analysis on major competitors operating in the market. The competitive analysis section includes analysis on various aspects associated with the key players, for instance, product synopsis, developments and innovations, key strategies, key personnel, geographical spread and other financials. These key players are continuously striving to grab a major portion of the market across the globe by expanding their footprint across regions. Companies such as MOTO, Widex A/S, GNNetcom (Jabra), Panasonic, Microsoft, Plantronics, Sennheiser, Samsung (Harman), Logitech (Jaybird), Bose and LG have been profiled in this research report.

According to Transparency Market Research, the global mono Bluetooth headsets market is projected to grow at a value CAGR of 7.3% during the period of forecast to reach a significant valuation of more than US$ 6 Bn by the end of the year of assessment.

*Download Sample PDF for Research Insights at* https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=39812

*Few Key Segmental Insights on Global Mono Bluetooth Headsets Market*

The global mono Bluetooth headsets market is segmented on the basis of product type, application, distribution channel and region.

With respect to region, North America and Europe are expected to show high market attractiveness in the coming years, with North America at the forefront. The mono Bluetooth headsets market in North America is estimated to reach a noteworthy market valuation by the end of the year of assessment. This market scenario in North America can be attributed to the increasing research and development in the technology sector associated with Bluetooth devices, increasing investments by number of players in developing new products and high per capita expenditure of people on mobile accessories. Europe region is expected to be the second largest in terms of market valuation. Mono Bluetooth headsets market in both North America and Europe regions is expected to grow at similar pace in the coming years. However, Asia Pacific excluding Japan (APEJ) region is expected to radiate high growth opportunities in the years to follow.

*Request a PDF Sample at *https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=39812

In the product type category, the HSP (Headset Profile) segment reflected high market share in 2017. This trend is expected to continue over the forecast period and this segment is estimated to reach a high market valuation of more than US$ 2 Bn by end of the year of assessment, thus leading the global market. Moreover, the Advanced Audio Distribution profile (A2DP) and the Hands Free Protocol (HFP) segments are expected to grow at a significant pace during the forecast period, however the latter is expected to showcase comparatively higher market strength and growth rate in the coming years. The adoption of Hands Free Protocol (HFP) is expected to increase at a high rate during the forecast period. This segment is thus anticipated to showcase high growth potential for mono Bluetooth headsets market.

With respect to application, the use of mono Bluetooth headsets for communication purposes has been increasing. The communication application segment is estimated to be the largest and is expected to dominate the global market. On the other hand, the sports segment is projected to expand at a high pace to register a value CAGR of 7.4% throughout the period of assessment.

By distribution channel, the multi branded stores segment is the largest with high market share and is expected to touch a value of about US$ 2300 Mn by the end of the year of assessment. In close competition, is the exclusive stores segment with a similar valuation, however a shade below the multi branded stores segment. The sales of mono Bluetooth headsets via multi branded stores and exclusive stores has been higher across the globe as compared to online sales channel and hypermarkets/supermarkets. However, the online sales channel is also expected to gain traction in the coming years.

*Get Discount on this Report at* https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=39812

*About Us*

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

*Contact Us*

Mr. Atil Chaudhari
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com
Research Blog: http://www.techyounme.com/ Reported by GlobeNewswire 7 minutes ago.
↧

NATO works on 'military Schengen' in Europe to strike Russia

March 12, 2018, 6:48 am
$
0
0
The Russian military leadership came to conclusion that the goal of the creation of the so-called "military Schengen" area in Europe was to accelerate the deployment of troops to the borders of Russia.Deputy Defense Minister Colonel-General Alexander Fomin said that such decisions became a new priority for NATO. Fomin said in an interview with the Krasnaya Zvezda newspaper that "the new priority of the military-political leadership of NATO is the improvement of the logistics and transport infrastructure within Europe, and the creation of the so-called" military Schengen" area. "The essence of the "military Schengen" is to move troops to Russian borders within the shortest period of time possible.The Deputy Minister of Defense of the Russian Federation noted that stocks of weapons, ammunition and food are being created for the rapid deployment of an additional group of troops in various parts of Europe.Presently, there are coordination centers in Estonia, Poland, Hungary, Romania, Lithuania, Latvia, Bulgaria and Slovakia.Pravda.Ru Read article on the Russian version of Pravda.Ru Reported by PRAVDA 3 minutes ago.
↧
Search

Inzaghi pleased to escape VAR in Europe

March 15, 2018, 6:14 am
$
0
0
Simone Inzaghi is pleased Lazio will not have to contend with VAR interrupting their Europa League last-16 second-leg clash with Dynamo Kiev on Thursday after frustrations in Serie A. Lazio have felt hard done by when it comes to the newly implemented technology in domestic matches, citing several instances where decision have gone against them. In […] Reported by SoccerNews.com 45 minutes ago.
↧
↧

Greece can do more to weed out corruption, watchdog agency says

March 15, 2018, 5:38 am
$
0
0
ATHENS (Reuters) - Greece should tighten the rules of conduct for its legislators and judiciary to prevent corruption, a senior official in the Council of Europe's anti-corruption agency said in an interview. Reported by Reuters 1 hour ago.
↧

World shares mixed, investors mull Trump choice of adviser

March 15, 2018, 5:49 am
$
0
0
Stocks are higher in Europe after a mixed day in Asia as investors assessed President Donald Trump's pick for his new economic adviser. Trading was in a narrow range with scant fresh leads. Reported by Newsday 1 hour ago.
↧

ePlus to Present at Wall Street Technology Association Cybersecurity Seminar

March 15, 2018, 5:37 am
$
0
0
HERNDON, Va., March 15, 2018 (GLOBE NEWSWIRE) -- ePlus inc. (NASDAQ:PLUS) announced today that it will be sponsoring and presenting at the Wall Street Technology Association (WSTA) seminar, “Next-Generation Cybersecurity: Implementing Effective Cybersecurity in a Time of Accelerating Threats.”  The seminar, being held March 22, 2018, at The Yale Club of New York City, provides an overview of the most critical threats facing Wall Street firms today.Darryl N. Ramsey, lead cybersecurity architect and strategist at ePlus, will present a session at 11:25 am on Customized Risk Management Frameworks.  He will discuss how internally-driven security standards and guidelines via frameworks are crucial in traversing today’s dynamic risk exposure landscape. His session will explore ways for security professionals to prioritize efforts in order to construct and mature a customized security program and discuss the fundamentals of achieving optimal results.

“ePlus is pleased to sponsor the WSTA seminar and share our risk management framework expertise with participants,” said Lee Waskevich, vice president of security solutions at ePlus.  “Security standards such as NIST, ISO, COBIT, and SANS help guide organizations towards best practices in cybersecurity.  While these standards provide guidance, they can also initiate confusion around applicability and priority that often result in delays or failure to take action.  Our session will explain why it is critical to assess the use of frameworks alongside current and future business initiatives to properly identify risk and determine risk tolerance.”

ePlus is a leader in cyber security services and creates custom, integrated programs that help customers prevent, defend against, and recover from malicious cyberattacks.  Through a holistic approach to securing data and developing strong risk management frameworks, ePlus enables organizations to reduce overall risk, build strong security cultures, and support innovation and digital transformation.  More information about ePlus’ security expertise and capabilities can be found at www.eplus.com/security.   

*About ePlus* *inc. *

ePlus is a leading consultative technology solutions provider that helps customers imagine, implement, and achieve more from their technology.  With the highest certifications from top technology partners and expertise in key technologies from cloud to security and digital infrastructure, ePlus transforms IT from a cost center to a business enabler.  Founded in 1990, ePlus has more than 1,200 associates serving a diverse set of customers in the U.S., Europe, and Asia-Pac.  The Company is headquartered at 13595 Dulles Technology Drive, Herndon, VA, 20171.  For more information, visit www.eplus.com, call 888-482-1122, or email info@eplus.com.  Connect with ePlus on Facebook at www.facebook.com/ePlusinc and on Twitter at www.twitter.com/ePlus.  ePlus. Where Technology Means More^®.

ePlus^®, Where Technology Means More^®, and ePlus products referenced herein are either registered trademarks or trademarks of ePlus inc. in the United States and/or other countries.  The names of other companies, products, and services mentioned herein may be the trademarks of their respective owners.

Statements in this press release that are not historical facts may be deemed to be “forward-looking statements.”  Actual and anticipated future results may vary materially due to certain risks and uncertainties, including, without limitation, possible adverse effects resulting from financial market disruption and general slowdown of the U.S. economy such as our current and potential customers delaying or reducing technology purchases, increasing credit risk associated with our customers and vendors, reduction of vendor incentive programs, and restrictions on our access to capital necessary to fund our operations; our ability to consummate and integrate acquisitions; the possibility of goodwill impairment charges in the future; significant adverse changes in, reductions in, or losses of relationships with major customers or vendors; the demand for and acceptance of, our products and services; our ability to adapt our services to meet changes in market developments; our ability to implement comprehensive plans for the integration of sales forces, cost containment, asset rationalization, systems integration and other key strategies; our ability to reserve adequately for credit losses; our ability to secure our electronic and other confidential information; future growth rates in our core businesses; the impact of competition in our markets; the possibility of defects in our products or catalog content data; our ability to adapt to changes in the IT industry and/or rapid change in product standards; our ability to realize our investment in leased equipment; our ability to hire and retain sufficient qualified personnel; and other risks or uncertainties detailed in our reports filed with the Securities and Exchange Commission.  All information set forth in this press release is current as of the date of this release and ePlus undertakes no duty or obligation to update this information.

Contact:
Kleyton Parkhurst, SVP
ePlus inc.
kparkhurst@eplus.com
*703-984-8150* Reported by GlobeNewswire 1 hour ago.
↧

Innovation Pharmaceuticals Views Brilacidin-OM as Clearly Differentiated Compared to Limited Competition for Preventing Severe Oral Mucositis

March 15, 2018, 5:37 am
$
0
0
BEVERLY, Mass., March 15, 2018 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals, (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to provide shareholders with a status report on the development of Brilacidin-OM, Innovation Pharma’s novel defensin mimetic drug candidate for the prevention and treatment of Severe Oral Mucositis (SOM) in Head and Neck Cancer (HNC) patients receiving chemoradiation. Over the last weeks, there has been significant attention directed to this disease. Additional perspectives on the SOM market—an area of great unmet medical need, attracting investment and industry attention – and the Company’s prospects in this emerging market are discussed.*Summary Points*

· *Brilacidin-OM viewed by Company to have significant competitive advantages and less challenges than other OM drug candidates:*
 

· *Prevention**: Effective reduction of SOM incidence, beyond providing symptom relief, would be a critical factor toward successful commercialization

*
· *Delivery: Brilacidin-OM developed in sachet packets offers a portable, quick-mixing, “instant” oral rinse therapy**—patients and providers likely would more readily adopt *
 
· *Cost**: Brilacidin-OM avoids costly manufacturing and logistics of sterile IV therapy competitors amid a regulatory environment demanding lower drug prices *
 

· *Company preparing for U.S. Food and Drug Administration (FDA) meeting to discuss Brilacidin-OM development plan*

The Company is currently focused on completing the Clinical Study Report for its Phase 2 clinical trial (see NCT02324335) evaluating Brilacidin’s ability to safely prevent and attenuate SOM in HNC patients receiving chemoradiation and compiling a Briefing Package for discussion with the FDA. The study’s primary endpoint was met, with Brilacidin, as a preventative treatment, showing a clear reduction in the incidence of SOM (WHO Grade ≥ 3) compared to placebo. A key secondary endpoint in the trial, delaying the onset of SOM, also was also met. Brilacidin is being developed under FDA Fast Track Designation.

*SOM Landscape*

In cases of SOM, patients cannot eat solid food (Grade 3) and cannot consume either solids or liquids (Grade 4)—a situation that can result in weight loss and, most critically, suspension of cancer therapy. As noted in a video on SOM published on the “Healthy Body, Healthy Mind” website, a loss of 10-to-15 pounds causes the incidence of cancer therapy side-effects to double; negative effects of developing SOM can also be overwhelming to a patient’s physical well-being and positive mental attitude.

There are currently no FDA-approved drugs for the prevention of SOM in HNC patients receiving chemoradiation. The additional inpatient expenses incurred when suffering from SOM are estimated to be as high as $18,000 to $25,000 per case in the U.S. when hospitalization is required. These two factors contribute to SOM qualifying as an area of significant unmet medical need.

According to published statistics, the number of annual new HNC cases in the U.S. is estimated to be 65,000 (worldwide, ~750,000 cases annually). Between 60 to 70 percent of these patients typically will develop SOM (confirmed in our own clinical study), with the overall incidence of HNC patients developing some grade of OM (WHO Grades 1 to 4) approaching 100 percent. Because it cannot be predicted which patients will develop SOM, a preventative treatment, such as Brilacidin-OM, would begin in all patients as soon as starting chemoradiation and continue until its completion (typically a seven-week course).

*Brilacidin-OM: A Leading SOM Drug Candidate*

The Company believes that Brilacidin-OM occupies a lead position among OM drug candidates currently advancing in clinical pipelines. Most of these potential competitor drugs target mainly symptom relief and not prevention of SOM, and/or are disadvantaged by not having as patient-friendly modes of delivery (e.g., IV) in comparison to oral rinse Brilacidin-OM. Given Brilacidin-OM is administered as a convenient and patient-friendly oral rinse, the Company believes that it would be attractive to both doctors and patients, which would translate to substantial market penetration should it one day gain regulatory approval. Innovation Pharma also believes that it would be a preferred treatment for payers due to being inherently less costly than IV infusion therapies.

Moreover, should Brilacidin-OM become an approved product in HNC, there likely would be an opportunity to broaden the label to cover preventative treatments for additional cancer markets involving chemotherapy and Hematopoietic Stem Cell Transplantation (HSCT) therapy. OM is a costly and frequent complication in these areas as well. This OM market, in aggregate, is estimated to comprise as many as 650,000 people annually in the U.S. (between 25 percent and 60 percent of all cancer patients receiving chemotherapy will experience OM). We believe most other competitor products, with less patient-friendly modes of delivery, would be less likely to reach this broader OM market.

Management recognizes unprecedented and newfound interest in the OM space, including the first-ever awarding of FDA Breakthrough Therapy designation for an experimental IV-administered OM drug. Increased industry efforts and regulatory attention toward advancing truly viable OM drugs, beyond simple oral coatings and “magic mouthwashes” that are readily available today, is fostering excitement among patients and physicians who await much-needed improvements in OM care. The emergence of different types of drug candidates, with varying efficacy and modes of delivery, will drive competition and add significant value to promising compounds, such as Brilacidin-OM.

*Brilacidin-OM: Sachet Development*

While already competitively advantaged as an oral rinse versus IV drug delivery, Innovation Pharma is actively exploring developing Brilacidin-OM as a sachet—an industry term for a small packet, similar to a common sugar packet. A sachet is easily transported and is less expensive than a liquid formulation and should be considerably less costly than a sterile IV drug for SOM. Add in the facility costs of multiple IV infusions per week over a treatment period of 6-7 weeks, and the cost can easily escalate (e.g. 1 hour of infusion, 5 days a week), which can severely limits a drug’s commercial prospects, especially if there are far less expensive alternatives. With a sachet, the Company envisions patients simply mixing the contents of the Brilacidin-OM sachet with water for a quick-and-easy treatment at home or on-the-go for the prevention of SOM.

In Other Company News:

The Prurisol Phase 2b clinical trial in Moderate-to-Severe Psoriasis remains blinded at present. Once the full dataset has been unblinded, received and reviewed, the Company will release the results. A novel psoriasis drug, particularly one that is oral, safe and effective, would be well-received by clinical practitioners and patients alike, and would likely command significant market value.

*Alerts*
Sign-up for Innovation Pharmaceuticals email alerts is available at:
http://www.ipharminc.com/email-alerts/

*About the Company *
Headquartered in Beverly, Massachusetts, Innovation Pharmaceuticals Inc. (IPI) is publicly-traded under the company symbol “IPIX”. The Company is a clinical stage biopharmaceutical company developing innovative therapies in multiple diseases. The Company believes it has a world-class portfolio of first-in-class lead drug candidates and is now advancing them toward market approval, while actively seeking strategic partnerships. The Company’s Psoriasis drug candidate Prurisol completed a Phase 2 trial and the Company has since conducted a Phase 2b study, with topline results expected in 2Q2018. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. The Company’s anti-cancer drug Kevetrin successfully concluded a Phase 1 clinical trial at Harvard Cancer Centers’ Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center and, more recently, a Phase 2 study in Ovarian Cancer. In the laboratory, Kevetrin has been shown to modulate p53, often referred to as the “Guardian Angel Gene” due to its crucial role in controlling cell mutations. Brilacidin, a defensin mimetic compound, has shown in an animal model to reduce the occurrence of severe ulcerative Oral Mucositis (OM) by more than 94% compared to placebo. The Company has recently completed a Phase 2 clinical trial with its novel compound Brilacidin-OM for the prevention of OM in patients with Head and Neck Cancer; topline results demonstrate a reduction in the incidence of severe OM (WHO Grade ≥ 3). The Company’s lead antibiotic, Brilacidin, has completed a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infection, or ABSSSI. The Phase 2b data showed a single dose of Brilacidin to deliver comparable clinical outcomes to the FDA-approved seven-day dosing regimen of daptomycin. Brilacidin has the potential to be a single-dose therapy for certain multi-drug resistant bacteria (“superbugs”). Positive results were also seen in the completed Phase 2, open label Proof-of-Concept trial, treating patients with Brilacidin for Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS), two types of Inflammatory Bowel Disease (IBD). The Company has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna. More information is available on the Company website at www.IPharmInc.com.

*Forward-Looking Statements*: This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 including statements concerning projected timelines for the initiation and completion of clinical trials, our future drug development plans, other statements regarding future product developments, including with respect to specific indications, and any other statements which are other than statements of historical fact. These statements involve risks, uncertainties and assumptions that could cause the Company’s actual results and experience to differ materially from anticipated results and expectations expressed in these forward-looking statements. The Company has in some cases identified forward-looking statements by using words such as “anticipates,” “believes,” “hopes,” “estimates,” “looks,” “expects,” “plans,” “intends,” “goal,” “potential,” “may,” “suggest,” and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are the Company’s need for, and the availability of, substantial capital in the future to fund its operations and research and development; including the amount and timing of the sale of shares of common stock to Aspire Capital; the fact that the Company’s compounds may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in the Company’s filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. The Company undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.

INVESTOR AND MEDIA CONTACT
Innovation Pharmaceuticals
Leo Ehrlich
info@IPharmInc.com Reported by GlobeNewswire 1 hour ago.
↧
↧

Europe Operating Room Equipment Market Analysis 2017-2023 - Anesthesia Devices, Tables, Endoscopes, Electrosurgical Devices, Operating Room Lights, Patient Monitors, Surgical Imaging Devices - ResearchAndMarkets.com

March 15, 2018, 5:44 am
$
0
0
The "Europe Operating Room Equipment Market Analysis (2017-2023)" report has been added to ResearchAndMarkets.com's offering. The Europe Operating Room Equipment market is expected to witness mark... Reported by FinanzNachrichten.de 1 hour ago.
↧

SELLAS Life Sciences Group Announces Notice of Allowance from U.S. Patent and Trademark Office for New Patent Covering Composition of Matter for WT-1 Peptides

March 15, 2018, 5:49 am
$
0
0
NEW YORK, March 15, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) (“SELLAS” or the “Company”), a clinical-stage biopharmaceutical company focused on novel cancer immunotherapies for a broad range of cancer indications, today announced that the U.S. Patent and Trademark Office (USPTO) issued a Notice of Allowance for U.S. Patent Application No. 14/760,997 related to certain Wilms Tumor 1 (WT1) peptides. The allowed patent application, entitled “Immunogenic WT-1 Peptides and Methods of Use Thereof,” is part of an intellectual property portfolio exclusively licensed from Memorial Sloan Kettering Cancer Center (MSKCC), which includes patent applications in major international markets. Issuance of the patent will expand the scope of protection of SELLAS’ intellectual property, which includes five U.S. patents and patent applications, as well as four international applications, which were filed under the Patent Cooperation Treaty, for galinpepimut-S (GPS), the Company’s Wilms Tumor 1-targeting immunotherapy, and pipeline technologies. The application includes claims to WT1 peptides having epitopes that provide further human leukocyte antigen (HLA) haplotype coverage, potentially broadening the applicability of WT1-based treatment strategies that utilize them. The terms of patent exclusivity on the component peptides extend to at least 2033 in the U.S.

“Together with the other granted patents and patent applications around GPS, this new patent will provide additional exclusivity for our product candidate pipeline,” stated Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS. “This Notice of Allowance for broad composition of matter claims is another important step forward for SELLAS that further strengthens and expands our WT1 intellectual property portfolio and regulatory exclusivity positions.”
  
SELLAS’ licensed patent portfolio includes several granted patents and pending patent applications in the U.S. and across Europe covering the peptide components of GPS, individually and in combination, as well as methods of using the peptides for the treatment of WT1-expressing cancers. Patents have been granted in the U.S. and across Europe with composition of matter claims covering each of the four peptides, individually and in combination, as well as methods of use covering treatment for cancer indications that SELLAS is pursuing in clinical trials. 

*About GPS*

GPS is a multi-component composition composed of four peptides derived from the WT1 protein, which has been ranked by the National Cancer Institute as a top priority among cancer antigens for immunotherapy.  Importantly, because the WT1 antigen is over-expressed in many malignancies, and is not found in most normal tissues, GPS has the potential to be a broad immunotherapy, effective across a multitude of diverse cancer types and patient populations. 

*About SELLAS Life Sciences Group*

SELLAS is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. SELLAS' lead product candidate, galinpepimut-S (GPS), is licensed from Memorial Sloan Kettering Cancer Center and targets the Wilms Tumor 1 (WT1) protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination to address a broad spectrum of hematologic malignancies and solid tumor indications. GPS has Phase 3 clinical trials planned (pending funding availability) for two indications, acute myeloid leukemia (AML) and malignant pleural mesothelioma (MPM). It is also in development as a potential treatment for multiple myeloma and ovarian cancer. SELLAS plans to study GPS in up to four additional indications. SELLAS has received Orphan Drug designations from the U.S. Food & Drug Administration (FDA), as well as the European Medicines Agency, for GPS in AML and MPM; GPS also received Fast Track designation for AML and MPM from the FDA.

For more information on SELLAS, please visit www.sellaslifesciences.com.

*Forward-Looking Statements*

This press release contains forward-looking statements, including, but not limited to, statements related to the expectations as to intellectual property protection and potential market and regulatory exclusivity for GPS, and the ability to further develop GPS for a broad range of cancer indications. These forward-looking statements are based on current plans, objectives, estimates, expectations and intentions, and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with cancer immunotherapy product development and clinical success thereof, attaining and maintenance of adequate intellectual property protection, the uncertainty of regulatory approval, and other risks and uncertainties affecting SELLAS and its development programs. Risks and uncertainties facing SELLAS are more fully described in SELLAS’s filings with the Securities and Exchange Commission, particularly in the section titled “Risk Factors.” Other risks and uncertainties of which SELLAS is not currently aware may also affect SELLAS’ forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements herein are made only as of the date hereof. SELLAS undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations or other circumstances that exist after the date as of which the forward-looking statements were made.

*Investor Contact:*
Will O’Connor
Stern Investor Relations, Inc.
212-362-1200
ir@sellaslife.com 

David Moser, JD
SELLAS Life Sciences Group
813-864-2571
info@sellaslife.com Reported by GlobeNewswire 1 hour ago.
↧
Search

Italian election results expose euro zone inadequacy

March 15, 2018, 6:01 am
$
0
0
Martin Wolf: Until prosperity is better distributed, Europe will remain vulnerable to upheaval Reported by Irish Times 58 minutes ago.
↧

Toe injury forces Barcelona midfielder Sergio Busquets out for three weeks

March 15, 2018, 6:15 am
$
0
0
Busquets was taken off for Andre Gomes in the 61st minute of Barca`s last-16 second leg against Chelsea, which the Catalans won 3-0 to go through to the quarter-finals of Europe`s elite club competition for an 11th consecutive year. Reported by Zee News 44 minutes ago.
↧
↧

Cambridge Innovation Center Closes $58 Million from HB Reavis

March 15, 2018, 6:09 am
$
0
0
CIC Partners with HB Reavis, Europe's Leading Innovative Workplace Provider, for Its Forthcoming 145K Square Foot Innovation Campus in Warsaw, Poland Cambridge Innovation Center (CIC) announced to... Reported by FinanzNachrichten.de 49 minutes ago.
↧

iCIMS to Participate in UNLEASH London Conference

March 15, 2018, 6:30 am
$
0
0
Holmdel, New Jersey, March 15, 2018 (GLOBE NEWSWIRE) -- iCIMS Inc., a leading provider of cloud-based talent acquisition solutions, announced today that the company will participate in the UNLEASH Conference & Expo to be held March 20-21, 2018 at the ExCeL London.

UNLEASH is the world’s fastest growing community focused on the future of work and the interface between people and technology. Leading topics from this year’s agenda include Brexit and its implications on an organization’s workforce, digital transformation, globalization, GDPR for HR, AI and automation, leadership crisis and company culture. Conference attendees can find iCIMS in the expo center at stand number 406.

“To help our customers remain competitive in an increasingly globalized work environment, we have upgraded many of iCIMS’ business practices in recent years, including launching an EU data center, opening an office in London, and building the next generation of Platform-as-a-Service to support customers who need to build their own applications to their needs,” said Chairman and CEO of iCIMS, Colin Day. “As GDPR approaches, we are deeply committed to supporting our UK and EU-based customers in achieving compliance within their hiring practices, and we look forward to seeing many of them at UNLEASH later this month,” added Day.

iCIMS supports more than 3,500 customers, including many global enterprise companies with a UK presence, making it one of the fastest-growing and largest providers in the space. iCIMS serves international customers such as Toyota Motor Europe, Sony Music Entertainment UK, AllSaints Retail Limited, Zizzi Restaurants, Endsleigh Insurance Services. In addition, iCIMS’ global customer base consists of dozens of Fortune 500 companies, including industry leaders in finance, healthcare, manufacturing and retail, such as Crate & Barrel, Foot Locker, Allstate Insurance Company, Enterprise Holdings, and Gold’s Gym.

As the hub of the talent acquisition technology ecosystem, iCIMS has a broad range of products and integrated partner applications to address recruiting requirements across all industries, helping companies to scale and successfully grow their business with top talent. The company recently announced strategic partnerships with tech industry icons that are new to the talent acquisition landscape such as Google, as well as long-standing human capital management (HCM) providers like ADP.

iCIMS will also be exhibiting at the UNLEASH Conference & Expo at the Aria Resort & Casino in Las Vegas on May 15-16, 2018.

For more information about UNLEASH London visit http://www.unleashgroup.io/london/index.

*About iCIMS, Inc.*

iCIMS is the leading provider of talent acquisition solutions that help businesses win the war for top talent. iCIMS empowers companies to manage their entire hiring process within the industry’s most robust Platform-as-a-Service (PaaS). Built on the foundation of a best-to-market talent acquisition software suite, iCIMS’ PaaS framework, UNIFi, allows employers to expand the capabilities of their core talent acquisition technology by integrating with the largest partner ecosystem in talent acquisition to help them attract, find, screen, and manage candidates. Offering scalable, easy-to-use solutions that are backed by award-winning customer service, iCIMS supports more than 3,500 contracted customers and is one of the largest and fastest-growing talent acquisition solution providers.

*About UNLEASH*

Unleash Your People! UNLEASH (previously HR Tech World) is much more than just business events; we are in the change-the-world-for-the-greater-good business. We are passionate creative people on a mission to inspire and transform the world of work & technology. Our shared vision is that by 2020, UNLEASH will be the platform of choice on the Future of Work across the globe. More than half of our community includes CEO's, CHRO/CPOs, EVPs, and SVPs from the most exciting brands and leading organizations, located in 120+ countries worldwide.

The world's fastest growing community on the Future of Work, UNLEASH is ranked as the largest Corporate Network focused on the interface between people, technology, organizations and the future. Our events attract the world's leading entrepreneurs, visionaries, disrupters and doers, including Sir Richard Branson, Arianna Huffington, Sir Ken Robinson, Rachel Botsman, Gary Vaynerchuk and many more. Past and future show locations include Amsterdam, London, San Francisco, Paris and Las Vegas and have welcomed over 9,000 attendees in 2017.

In 2018, UNLEASH will scale significantly to become the world's leading marketplace and community on the future of the workplace and technology. Join the community and find out more at www.unleashgroup.io.

Attachment:

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/19c14dbe-8023-4115-ac82-c6a4ff5508c9

CONTACT: Carlee Pett
iCIMS, Inc.
7325207453
carlee.pett@icims.com Reported by GlobeNewswire 29 minutes ago.
↧

InterDigital Congratulates Bristol on Smart City GLOMO Win

March 15, 2018, 6:30 am
$
0
0
WILMINGTON, Del., March 15, 2018 (GLOBE NEWSWIRE) -- InterDigital, Inc. (NASDAQ:IDCC), a mobile technology research and development company, congratulates Bristol on its 2018 Global Mobile Awards (GLOMO) win for Bristol is Open in the category, Smart City—The Judges’ Choice. According to the judges, Bristol was given the award based on the strong IoT network testbed and the city operations center it has built as part of the Bristol is Open (BIO) initiative, the region’s programmable city project.BIO is a collaborative initiative jointly governed by the Bristol City Council and the University of Bristol. Together with technology, media, telecommunications industry and local, regional and national government, BIO is on a mission to transform the way this UK city operates through the use of smart technology.

To achieve this mission, Bristol has formed important collaborations with leading companies in the technology, media and telecommunications sector. As one of these partners, InterDigital has made a positive contribution to prove the technology within the BIO test bed.

In August 2017, InterDigital conducted a joint trial with BIO to demonstrate the capabilities of InterDigital’s Flexible IP-based Services (FLIPS) solution. InterDigital has collaborated further with BIO on various projects including RIFE, a trial aiming to address the major societal challenge of providing affordable internet by solving the technological challenges of 5G, and on the H2020 Europe FLAME project, which saw the launch of the first urban-scale 5G test bed in Bristol and Barcelona.

Bristol was chosen for the award from among several other leading smart cities, including Barcelona, Dubai, New York, Singapore and Yinchuan.

Jim Nolan, Executive Vice President, Products, InterDigital, said: “We are delighted to see an innovative city such as Bristol be awarded one of the telecoms industry’s most prestigious awards. As a partner, we’re committed to helping cities like Bristol innovate and develop in a way that harnesses the capabilities of new and emerging technologies. This award further reinforces both the work Bristol is doing towards the development of smart cities and the work that we, as a partner, and as an industry, are doing to collaborate to make these new developments happen.”

*About InterDigital**^®*

InterDigital develops mobile technologies that are at the core of devices, networks, and services worldwide. We solve many of the industry's most critical and complex technical challenges, inventing solutions for more efficient broadband networks and a richer multimedia experience years ahead of market deployment. InterDigital has licenses and strategic relationships with many of the world's leading wireless companies. Founded in 1972, InterDigital is listed on NASDAQ and is included in the S&P MidCap 400^® index.

InterDigital is a registered trademark of InterDigital, Inc.

For more information, visit: www.interdigital.com.

*InterDigital Contact:*
Patrick Van de Wille
Email: patrick.vandewille@interdigital.com
+1 (858) 210-4814  

  Reported by GlobeNewswire 29 minutes ago.
↧
Viewing all 65275 articles
Browse latest View live
More Pages to Explore .....
Search

Latest Images

Nonprofit donates custom home in this East Bay city for Marine injured in...

Nonprofit donates custom home in this East Bay city for Marine injured in...

April 23, 2024, 7:00 am
New private rooms on Tokaido Shinkansen change the way we travel from Tokyo...

New private rooms on Tokaido Shinkansen change the way we travel from Tokyo...

April 22, 2024, 6:00 am
Ukraine bans military from online gambling amid addiction concerns

Ukraine bans military from online gambling amid addiction concerns

April 22, 2024, 5:17 am
ಮಂಡ್ಯದಿಂದ ಸುಮಲತಾ ದೂರ; ಹೆಚ್‌ಡಿಕೆ ಪರ ಪ್ರಚಾರಕ್ಕಿಳಿಯದ ಸಂಸದೆ –ಬರ್ತಾರೆ ನೋಡೋಣ ಎಂದ...

ಮಂಡ್ಯದಿಂದ ಸುಮಲತಾ ದೂರ; ಹೆಚ್‌ಡಿಕೆ ಪರ ಪ್ರಚಾರಕ್ಕಿಳಿಯದ ಸಂಸದೆ –ಬರ್ತಾರೆ ನೋಡೋಣ ಎಂದ...

April 20, 2024, 8:08 pm
OCBC Bank Singapore Offers Up to 2.8% p.a. Fixed Deposit Promotion from 21...

OCBC Bank Singapore Offers Up to 2.8% p.a. Fixed Deposit Promotion from 21...

April 20, 2024, 12:38 pm
National Poetry Month 2024: Maxine Starr

National Poetry Month 2024: Maxine Starr

April 19, 2024, 9:56 am
Vegan Chicken Pot Pie

Vegan Chicken Pot Pie

April 19, 2024, 9:18 am
Firefox UX: On Purpose: Collectively Defining Our Team’s Mission Statement

Firefox UX: On Purpose: Collectively Defining Our Team’s Mission Statement

April 19, 2024, 7:03 am
New $4.5 million East Bay trail path will connect bicyclists, pedestrians to...

New $4.5 million East Bay trail path will connect bicyclists, pedestrians to...

April 18, 2024, 11:05 am
Photographer Gifts for Clients / Print Packaging / 4x6 Photo Box by...

Photographer Gifts for Clients / Print Packaging / 4x6 Photo Box by...

April 17, 2024, 6:48 pm